Home › Funds › STRAIGHTLINE GROUP LLC › AMRX
STRAIGHTLINE GROUP LLC position in AMRX
AMNEAL PHARMACEUTICALS INC · Health Care
STRAIGHTLINE GROUP LLC reported holding 10,600 shares of AMRX (AMNEAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$213K, representing 0.15% of its reported portfolio and ranking #17 among its reported holdings. STRAIGHTLINE GROUP LLC has disclosed AMRX holdings in 2 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-10 · Source: SEC EDGAR Form 13F-HR
How STRAIGHTLINE GROUP LLC's AMRX position evolved
STRAIGHTLINE GROUP LLC first disclosed a stake in AMRX in Q4 2024 at 11,600 shares (US$92K). The position peaked in Q3 2026 at 10,600 shares, worth US$213K. Across 2 filings, STRAIGHTLINE GROUP LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 10,600 shares valued at US$213K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 11.60K | $91.87K | New |
| Q3 2026 | 10.60K | $213.48K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMRX and 13F data
AMRX (AMNEAL PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in AMRX — the largest reported positions include TPG GP A, LLC (US$213.4M), Rubric Capital Management LP (US$176.0M), Nantahala Capital Management, LLC (US$39.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMRX
- TPG GP A, LLC 12.33M sh · $213.41M · Q2 2026
- Rubric Capital Management LP 10.17M sh · $176.02M · Q2 2026
- Nantahala Capital Management, LLC 2.27M sh · $39.27M · Q2 2026
- Westshore Wealth, LLC 1.37M sh · $23.65M · Q2 2026
- BlackBarn Capital Partners LP 1.30M sh · $22.50M · Q2 2026
- Penn Capital Management Company, LLC 1.18M sh · $20.48M · Q2 2026
- TUCKER ASSET MANAGEMENT LLC 1.01M sh · $17.50M · Q2 2026
- Phocas Financial Corp. 819.48K sh · $14.19M · Q2 2026
More on STRAIGHTLINE GROUP LLC
FAQ
How long has STRAIGHTLINE GROUP LLC held AMRX?
STRAIGHTLINE GROUP LLC has disclosed AMRX holdings in 2 of the last 8 reported quarters, going back to Q4 2024.
What is STRAIGHTLINE GROUP LLC's current position in AMRX?
As of Q3 2026, STRAIGHTLINE GROUP LLC holds 10.60K shares of AMRX (AMNEAL PHARMACEUTICALS INC), valued at $213.48K, representing 0.15% of its reported portfolio and ranking #17.
Has STRAIGHTLINE GROUP LLC been buying or selling AMRX?
In the latest 13F filing (Q3 2026), STRAIGHTLINE GROUP LLC newly opened its position in AMRX. The position peaked in Q3 2026 at 10.60K shares.
Which other funds hold AMRX?
Other major institutional holders of AMRX include TPG GP A, LLC, Rubric Capital Management LP, Nantahala Capital Management, LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.